Merck's Personalized Cancer Vaccine Shows Success in Late-Stage Melanoma Trial
On August 19, 2026, Merck (MRK) announced that its personalized cancer vaccine, developed with Moderna (MRNA), successfully met key endpoints in a Phase 3 trial for melanoma. The treatment combination of Intismeran and Keytruda improved recurrence-free survival and distant metastasis-free survival compared to Keytruda alone. This breakthrough led to an immediate market reaction: Merck's stock surged by about 12.5%, adding approximately $43 billion in value within hours. The success is particularly significant for Merck as it faces the expiration of its top-selling drug, Keytruda’s patent protection in 2028. Analysts suggest that this vaccine could serve as a long-term revenue replacement due to its personalized nature and limited generic competition potential. While peak annual sales estimates are around $4.3 billion globally for melanoma treatment alone, the market appears to be valuing broader applications of the technology across other cancers. Goldman Sachs analysts noted that Merck's stock had lower expectations prior to this announcement, allowing room for a sharp upward move upon positive results. The trial outcome validated both the scientific approach and Merck’s strategic direction post-Keytruda exclusivity loss.
Topics: cancer vaccine clinical trial success Merck Moderna partnership